Zobrazeno 1 - 10
of 61
pro vyhledávání: '"Local/drug therapy"'
Autor:
Dijkstra, E A, Zwart, W H, Nilsson, P J, Putter, H, Roodvoets, A G H, Meershoek-Klein Kranenbarg, E, Frödin, J E, Nygren, P, Østergaard, L, Kersten, C, Verbiené, I, Cervantes, A, Hendriks, M P, Capdevila, J, Edhemovic, I, van de Velde, C J H, Marijnen, C A M, van Etten, B, Hospers, G A P, Glimelius, B
Publikováno v:
Dijkstra, E A, Zwart, W H, Nilsson, P J, Putter, H, Roodvoets, A G H, Meershoek-Klein Kranenbarg, E, Frödin, J E, Nygren, P, Østergaard, L, Kersten, C, Verbiené, I, Cervantes, A, Hendriks, M P, Capdevila, J, Edhemovic, I, van de Velde, C J H, Marijnen, C A M, van Etten, B, Hospers, G A P, Glimelius, B & collaborative investigators 2023, ' The value of post-operative chemotherapy after chemoradiotherapy in patients with high-risk locally advanced rectal cancer-results from the RAPIDO trial ', ESMO Open, vol. 8, no. 2, 101158 . https://doi.org/10.1016/j.esmoop.2023.101158
ESMO Open, 8(2):101158. BMJ PUBLISHING GROUP
ESMO Open, 8(2):101158. BMJ PUBLISHING GROUP
BACKGROUND: Pre-operative chemoradiotherapy (CRT) rather than radiotherapy (RT) has resulted in fewer locoregional recurrences (LRRs), but no decrease in distant metastasis (DM) rate for patients with locally advanced rectal cancer (LARC). In many co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3480a3bcc64f6498babb69a11b0eb0da
https://vbn.aau.dk/da/publications/df0ee981-931d-4ca3-8ec9-5fe0e0ab0b06
https://vbn.aau.dk/da/publications/df0ee981-931d-4ca3-8ec9-5fe0e0ab0b06
Autor:
Van Nyen, Tom, Planque, Mélanie, van Wagensveld, Lilian, Duarte, Joao A.G., Zaal, Esther A., Talebi, Ali, Rossi, Matteo, Körner, Pierre René, Rizzotto, Lara, Moens, Stijn, De Wispelaere, Wout, Baiden-Amissah, Regina E.M., Sonke, Gabe S., Horlings, Hugo M., Eelen, Guy, Berardi, Emanuele, Swinnen, Johannes V., Berkers, Celia R., Carmeliet, Peter, Lambrechts, Diether, Davidson, Ben, Agami, Reuven, Fendt, Sarah Maria, Annibali, Daniela, Amant, Frédéric, Veterinaire biochemie, Faculteit Diergeneeskunde, Sub Biomol.Mass Spectrometry & Proteom., Biomolecular Mass Spectrometry and Proteomics
Publikováno v:
Nature communications, 13(1):4578. Nature Publishing Group
Nature Communications, 13(1):4578. Nature Publishing Group
Van Nyen, T, Planque, M, van Wagensveld, L, Duarte, J A G, Zaal, E A, Talebi, A, Rossi, M, Körner, P R, Rizzotto, L, Moens, S, De Wispelaere, W, Baiden-Amissah, R E M, Sonke, G S, Horlings, H M, Eelen, G, Berardi, E, Swinnen, J V, Berkers, C R, Carmeliet, P, Lambrechts, D, Davidson, B, Agami, R, Fendt, S M, Annibali, D & Amant, F 2022, ' Serine metabolism remodeling after platinum-based chemotherapy identifies vulnerabilities in a subgroup of resistant ovarian cancers ', Nature Communications, vol. 13, no. 1, 4578 . https://doi.org/10.1038/s41467-022-32272-6
Nature Communications, 13(1), 1. Nature Publishing Group
Nature Communications
Nature Communications, 13(1):4578. Nature Publishing Group
Van Nyen, T, Planque, M, van Wagensveld, L, Duarte, J A G, Zaal, E A, Talebi, A, Rossi, M, Körner, P R, Rizzotto, L, Moens, S, De Wispelaere, W, Baiden-Amissah, R E M, Sonke, G S, Horlings, H M, Eelen, G, Berardi, E, Swinnen, J V, Berkers, C R, Carmeliet, P, Lambrechts, D, Davidson, B, Agami, R, Fendt, S M, Annibali, D & Amant, F 2022, ' Serine metabolism remodeling after platinum-based chemotherapy identifies vulnerabilities in a subgroup of resistant ovarian cancers ', Nature Communications, vol. 13, no. 1, 4578 . https://doi.org/10.1038/s41467-022-32272-6
Nature Communications, 13(1), 1. Nature Publishing Group
Nature Communications
Resistance to platinum-based chemotherapy represents a major clinical challenge for many tumors, including epithelial ovarian cancer. Patients often experience several response-relapse events, until tumors become resistant and life expectancy drops t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32f6620652620504779c305788adf25e
https://pure.eur.nl/en/publications/6673c7ab-c247-464e-8cfb-c59f06484e27
https://pure.eur.nl/en/publications/6673c7ab-c247-464e-8cfb-c59f06484e27
Autor:
Maria S. Lindgren, Erik Hansen, Nessn Azawi, Anna M. Nielsen, Lars Dyrskjøt, Jørgen B. Jensen
Publikováno v:
Skydt Lindgren, M, Hansen, E B, Azawi, N H, Munk Nielsen, A, Dyrskjøt, L & Jensen, J B 2023, ' DaBlaCa-13 Study: Oncological Outcome of Short-Term, Intensive Chemoresection With Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial ', Journal of Clinical Oncology, vol. 41, no. 2, 41, pp. 206-211 . https://doi.org/10.1200/JCO.22.00470
PURPOSE This study aimed to assess long-term follow-up after chemoresection with mitomycin (MMC), a nonsurgical treatment modality for recurrent nonmuscle invasive bladder cancer (NMIBC). At the time of recurrence, chemoresection has previously been
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae14f3fcdac801099e554f706c3f022a
https://pure.au.dk/portal/da/publications/dablaca13-study-oncological-outcome-of-shortterm-intensive-chemoresection-with-mitomycin-in-nonmuscle-invasive-bladder-cancer-primary-outcome-of-a-randomized-controlled-trial(e88f9de7-59e2-4940-b972-938bd9cba8dd).html
https://pure.au.dk/portal/da/publications/dablaca13-study-oncological-outcome-of-shortterm-intensive-chemoresection-with-mitomycin-in-nonmuscle-invasive-bladder-cancer-primary-outcome-of-a-randomized-controlled-trial(e88f9de7-59e2-4940-b972-938bd9cba8dd).html
Autor:
Andersen, Claus L, Heitzer, Ellen
Publikováno v:
Andersen, C L & Heitzer, E 2022, ' ctDNA-guided adjuvant chemotherapy for colorectal cancer-ready for prime time? ', Cancer Cell, vol. 40, no. 9, pp. 911-913 . https://doi.org/10.1016/j.ccell.2022.08.017
In stage II colorectal cancer, adjuvant chemotherapy is controversial, and overtreatment is substantial due to suboptimal risk stratification. In a recent New England Journal of Medicine article reporting from a prospective randomized phase II trial,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::631d82b8deda3384a3cc1a80e35945c4
https://doi.org/10.1016/j.ccell.2022.08.017
https://doi.org/10.1016/j.ccell.2022.08.017
Autor:
Oshima, Takashi, Tsuburaya, Akira, Yoshida, Kazuhiro, Yoshikawa, Takaki, Miyagi, Yohei, Rino, Yasushi, Masuda, Munetaka, Guan, Jia, Tan, Patrick, Grabsch, Heike I, Sakamoto, Junichi, Tanaka, Shiro
Publikováno v:
Scientific Reports, 12(1):8509. Nature Publishing Group
Biomarkers for selecting gastric cancer (GC) patients likely to benefit from sequential paclitaxel treatment followed by fluorinated-pyrimidine-based adjuvant chemotherapy (sequential paclitaxel) were investigated using tissue samples of patients rec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38d9b4e8b52dc1b544df3051ce391d73
https://doi.org/10.1038/s41598-022-12439-3
https://doi.org/10.1038/s41598-022-12439-3
Autor:
Plätzer, Eva
Das Mammakarzinom ist mit jährlich 1,4 Millionen Neuerkrankungen weltweit die häufigste maligne Tumorerkrankung und ebenso mit jährlich 460.000 Todesfällen weltweit die häufigste durch ein Malignom bedingte Todesursache der Frau (Jemal et al., 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1224c80690dd2d0c1e3de6670ef481f2
https://epub.uni-regensburg.de/53163/
https://epub.uni-regensburg.de/53163/
Autor:
Janssen, J, Staal, F H E, Brouwer, C L, Langendijk, J A, de Jong, I J, van Moorselaar, R J A, Schuit, E, Verzijlbergen, J F, Smeenk, R J, Aluwini, S
Publikováno v:
BMC Cancer, 22
BMC Cancer, 22(1):482. BioMed Central
BMC Cancer, 22, 1
Janssen, J, Staal, F H E, Brouwer, C L, Langendijk, J A, de Jong, I J, van Moorselaar, R J A, Schuit, E, Verzijlbergen, J F, Smeenk, R J & Aluwini, S 2022, ' Androgen Deprivation therapy for Oligo-recurrent Prostate cancer in addition to radioTherapy (ADOPT) : study protocol for a randomised phase III trial ', BMC Cancer, vol. 22, no. 1, 482 . https://doi.org/10.1186/s12885-022-09523-2
BMC Cancer, 22(1):482. BMC
BMC Cancer, 22(1):482. BioMed Central
BMC Cancer, 22, 1
Janssen, J, Staal, F H E, Brouwer, C L, Langendijk, J A, de Jong, I J, van Moorselaar, R J A, Schuit, E, Verzijlbergen, J F, Smeenk, R J & Aluwini, S 2022, ' Androgen Deprivation therapy for Oligo-recurrent Prostate cancer in addition to radioTherapy (ADOPT) : study protocol for a randomised phase III trial ', BMC Cancer, vol. 22, no. 1, 482 . https://doi.org/10.1186/s12885-022-09523-2
BMC Cancer, 22(1):482. BMC
Background More than 60% of oligo-recurrent prostate cancer (PCa) patients treated with metastasis-directed radiotherapy (MDRT) develop biochemical recurrence within 2 years. This recurrence rate emphasises the need for improved treatment and patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66d2a1590219078a953368fea083c2ad
http://hdl.handle.net/2066/250165
http://hdl.handle.net/2066/250165
Autor:
Sebastian Søby, Anita Gothelf, Niels Gyldenkerne, Jens Bentzen, Kinga Nowicka-Matus, Trine Tramm, Jesper Grau Eriksen
Publikováno v:
Søby, S, Gothelf, A, Gyldenkerne, N, Bentzen, J, Nowicka-Matus, K, Tramm, T & Eriksen, J G 2022, ' Efficacy of nivolumab as second line treatment for recurrent or metastatic head and neck squamous cell carcinoma : a national DAHANCA cohort study ', Acta Oncologica, vol. 61, no. 8, pp. 972-978 . https://doi.org/10.1080/0284186X.2022.2103387
Søby, S, Gothelf, A, Gyldenkerne, N, Bentzen, J, Nowicka-Matus, K, Tramm, T & Eriksen, J G 2022, ' Efficacy of nivolumab as second line treatment for recurrent or metastatic Head and Neck Squamous Cell Carcinoma : A national DAHANCA cohort study ', Acta Oncologica, vol. 61, no. 8, pp. 972-978 . https://doi.org/10.1080/0284186X.2022.2103387
Søby, S, Gothelf, A, Gyldenkerne, N, Bentzen, J, Nowicka-Matus, K, Tramm, T & Eriksen, J G 2022, ' Efficacy of nivolumab as second line treatment for recurrent or metastatic Head and Neck Squamous Cell Carcinoma : A national DAHANCA cohort study ', Acta Oncologica, vol. 61, no. 8, pp. 972-978 . https://doi.org/10.1080/0284186X.2022.2103387
Introduction: The aim of this study was to investigate phase IV efficacy, of the PD-1 inhibitor nivolumab among an unselected and unbiased national cohort of recurrent/metastatic Head and Neck Squamous Cell Carcinoma (rmHNSCC) patients. Material and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6223af21be2cc40e5ee4aef8d457eea
https://pubmed.ncbi.nlm.nih.gov/35913523
https://pubmed.ncbi.nlm.nih.gov/35913523
Autor:
Linnéa Schmidt, Issa Ismail Issa, Hulda Haraldsdóttir, Jonas Laugård Hald, Alexander Schmitz, Hanne Due, Karen Dybkær
Publikováno v:
Schmidt, L, Issa, I I, Haraldsdóttir, H, Hald, J L, Schmitz, A, Due, H & Dybkær, K 2022, ' Hsp90 inhibition sensitizes DLBCL cells to cisplatin ', Cancer Chemotherapy and Pharmacology, vol. 89, no. 4, pp. 431-440 . https://doi.org/10.1007/s00280-022-04407-5
Schmidt, L, Issa, I I, Haraldsdóttir, H, Hald, J L, Due, H & Dybkær, K 2022, ' Hsp90 inhibition sensitizes DLBCL cells to cisplatin ', Cancer Chemotherapy and Pharmacology, vol. 89, no. 4, pp. 431-440 . https://doi.org/10.1007/s00280-022-04407-5
Schmidt, L, Issa, I I, Haraldsdóttir, H, Hald, J L, Due, H & Dybkær, K 2022, ' Hsp90 inhibition sensitizes DLBCL cells to cisplatin ', Cancer Chemotherapy and Pharmacology, vol. 89, no. 4, pp. 431-440 . https://doi.org/10.1007/s00280-022-04407-5
PurposePlatinum-containing therapy is standard treatment for relapsed Diffuse Large B-Cell Lymphoma (DLBCL). However, the efficacy of treatment is limited by drug resistance leading to relapse. Cisplatin resistance has been linked to impairments of t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95c3d1875eb090fc0377fa24b24ad23b
https://vbn.aau.dk/ws/files/468426671/Schmidt_et_al._2022_._Hsp90_inhibition_sensitizes_DLBCL_cells_to_cisplatin.pdf
https://vbn.aau.dk/ws/files/468426671/Schmidt_et_al._2022_._Hsp90_inhibition_sensitizes_DLBCL_cells_to_cisplatin.pdf
Autor:
Emma V. Jones, Joon Rhee, Jérôme Alexandre, Zhongwu Lai, L Opincar, Matthew G Krebs, Yeon Hee Park, Jean Pierre Delord, Antoine Italiano, Anna M. L. Coenen-Stass, Seock-Ah Im, Sara Bastian, Sophie Postel-Vinay, Sakshi Gulati, Susan M. Domchek, Ding Wang, Saiama N. Waqar, Haiyan Gao, Benoit You, P. Herbolsheimer, M. Lanasa, Helen K. Angell, Iwanka Kozarewa, Vidalba Rocher-Ros, Bella Kaufman
Publikováno v:
Domchek, S M, Postel-Vinay, S, Im, S-A, Park, Y H, Delord, J-P, Italiano, A, Alexandre, J, You, B, Bastian, S, Krebs, M G, Wang, D, Waqar, S N, Lanasa, M, Rhee, J, Gao, H, Rocher-Ros, V, Jones, E V, Gulati, S, Coenen-Stass, A, Kozarewa, I, Lai, Z, Angell, H K, Opincar, L, Herbolsheimer, P & Kaufman, B 2020, ' Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA) : an open-label, multicentre, phase 1/2, basket study ', The Lancet. Oncology, vol. 21, no. 9, pp. 1155-1164 . https://doi.org/10.1016/S1470-2045(20)30324-7
BACKGROUND: Poly (ADP-ribose) polymerase inhibitors combined with immunotherapy have shown antitumour activity in preclinical studies. We aimed to assess the safety and activity of olaparib in combination with the PD-L1-inhibitor, durvalumab, in pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c34416fb3adf2a299c05113cf960a2c
https://doi.org/10.1016/s1470-2045(20)30324-7
https://doi.org/10.1016/s1470-2045(20)30324-7